Targeting the Nucleotide Excision Repair Pathway for Therapeutic Applications

DNA Repair in Cancer Therapy

Volumn , Issue , 2012, Pages 109-117

  Turchi, John J ^a   Patrick, Steve M ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TOLEDO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882322443     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-384999-1.10006-X     Document Type: Chapter

References (89)

1. Araujo S.J., Tirode F., Coin F., et al. Nucleotide excision repair of DNA with recombinant human proteins: definition of the minimal set of factors, active forms of TFIIH, and modulation by CAK. Genes Devel 2000, 14(3):349-359.
2. Reardon J.T., Sancar A. Nucleotide excision repair. Progr Nucl Acid Res Mol Biol 2005, 79:183-235.
3. Sugasawa K. UV-DDB: A molecular machine linking DNA repair with ubiquitination. DNA Repair (Amst) 2009, 8(8):969-972.
4. El-Mahdy M.A., Zhu Q., Wang Q.E., Wani G., Praetorius-Ibba M., Wani A.A. Cullin 4A-mediated proteolysis of DDB2 protein at DNA damage sites regulates in vivo lesion recognition by XPC. J Biol Chem 2006, 281(19):13404-13411.
5. Sugasawa K., Okuda Y., Saijo M., et al. UV-induced ubiquitylation of XPC protein mediated by UV-DDB-ubiquitin ligase complex. Cell 2005, 121(3):387-400.
6. Chen X., Zhang Y., Douglas L., Zhou P. UV-damaged DNA-binding proteins are targets of CUL-4A-mediated ubiquitination and degradation. J Biol Chem 2001, 276(51):48175-48182.
7. Nag A., Bondar T., Shiv S., Raychaudhuri P. The xeroderma pigmentosum group E gene product DDB2 is a specific target of cullin 4A in mammalian cells. Mol Cell Biol 2001, 21(20):6738-6747.
8. Sugasawa K., Okamoto T., Shimizu Y., Masutani C., Iwai S., Hanaoka F. A multistep damage recognition mechanism for global genomic nucleotide excision repair. Genes Devel 2001, 15(5):507-521.
9. Dip R., Camenisch U., Naegeli H. Mechanisms of DNA damage recognition and strand discrimination in human nucleotide excision repair. DNA Repair 2004, 3(11):1409-1423.
10. Laine J.P., Mocquet V., Egly J.M. TFIIH enzymatic activities in transcription and nucleotide excision repair. DNA Repair Pt A 2006, 408:246-263.
11. Staresincic L., Fagbemi A.F., Enzlin J.H., et al. Coordination of dual incision and repair synthesis in human nucleotide excision repair. EMBO J 2009, 28(8):1111-1120.
12. Moser J., Kool H., Giakzidis I., Caldecott K., Mullenders L.H., Fousteri M.I. Sealing of chromosomal DNA nicks during nucleotide excision repair requires XRCC1 and DNA ligase III alpha in a cell-cycle-specific manner. Mol Cell 2007, 27(2):311-323.
13. Mocquet V., Laine J.P., Riedl T., Yajin Z., Lee M.Y., Egly J.M. Sequential recruitment of the repair factors during NER: the role of XPG in initiating the resynthesis step. EMBO J 2008, 27(1):155-167.
14. Nouspikel T. Nucleotide excision repair and neurological diseases. DNA Repair (Amst) 2008, 7(7):1155-1167.
15. Aboussekhra A., Biggerstaff M., Shivji M.K., et al. Mammalian DNA nucleotide excision repair reconstituted with purified protein components. Cell 1995, 80(6):859-868.
16. Laine J.P., Egly J.M. When transcription and repair meet: a complex system. Trends Genet 2006, 22(8):430-436.
17. Ueda T., Compe E., Catez P., Kraemer K.H., Egly J.M. Both XPD alleles contribute to the phenotype of compound heterozygote xeroderma pigmentosum patients. J Exp Med 2009, 206(13):3031-3046.
18. Nardo T., Oneda R., Spivak G., et al. A UV-sensitive syndrome patient with a specific CSA mutation reveals separable roles for CSA in response to UV and oxidative DNA damage. Proc Natl Acad Sci USA 2009, 106(15):6209-6214.
19. Horibata K., Iwamoto Y., Kuraoka I., et al. Complete absence of Cockayne syndrome group B gene product gives rise to UV-sensitive syndrome but not Cockayne syndrome. Proc Natl Acad Sci USA 2004, 101(43):15410-15415.
20. Itoh T., Ono T., Yamaizumi M. A new UV-sensitive syndrome not belonging to any complementation groups of xeroderma pigmentosum or Cockayne syndrome: siblings showing biochemical characteristics of Cockayne syndrome without typical clinical manifestations. Mutat Res 1994, 314(3):233-248.
21. Cleaver J.E. Splitting hairs - discovery of a new DNA repair and transcription factor for the human disease trichothiodystrophy. DNA Repair 2005, 4(2):285-287.
22. Coin F., De Santis L.P., Nardo T., Zlobinskaya O., Stefanini M., Egly J.M. P8/TTD-A as a repair-specific TFIIH subunit. Molecular Cell 2006, 21(2):215-226.
23. Cohen S.M., Lippard S.J. Cisplatin: From DNA damage to cancer chemotherapy. Progr Nucl Acid Res Mol Biol 2001, 67:93-130.
24. Leng M., Brabec V. DNA adducts of cisplatin, transplatin and platinum-intercalating drugs. [Review] [53 refs]. IARC Scientific Publications 1994, 125:339-348.
25. Takahara P.M., Frederick C.A., Lippard S.J. Crystal structure of the anticancer drug cisplatin bound to duplex DNA. J Am Chem Soc 1996, 118:12309-12321.
26. Dijt F.J., Fichtinger-Schepman A.M., Berends F., Reedijk J. Formation and repair of cisplatin-induced adducts to DNA in cultured normal and repair-deficient human fibroblasts. Cancer Res 1988, 48(21):6058-6062.
27. Koberle B., Grimaldi K.A., Sunters A., Hartley J.A., Kelland L.R., Masters J.R.W. DNA repair capacity and cisplatin sensitivity of human testis tumour cells. Int J Cancer 1997, 70(5):551-555.
28. Koberle B., Masters J.R.W., Hartley J.A., Wood R.D. Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr Biol 1999, 9(5):273-276.
29. Welsh C., Day R., McGurk C., Masters J.R.W., Wood R.D., Koberle B. Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines. Int J Cancer 2004, 110(3):352-361.
30. Koberle B., Roginskaya V., Wood R.D. XPA protein as a limiting factor for nucleotide excision repair and UV sensitivity in human cells. DNA Repair (Amst) 2006, 5(5):641-648.
31. Usanova S., Piee-Staffa A., Sied U., et al. Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression. Mol Cancer 2010, 9:248.
32. Altaha R., Liang X., Yu J.J., Reed E. Excision repair cross complementing-group 1: gene expression and platinum resistance. Int J Mol Med 2004, 14(6):959-970.
33. Masuda H., Ozols R.F., Lai G.M., Fojo A., Rothenberg M., Hamilton T.C. Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. Cancer Res 1988, 48(20):5713-5716.
34. Lieber M.R. The FEN-1 family of structure-specific nucleases in eukaryotic DNA replication, recombination and repair. Bioessays 1997, 19(3):233-240.
35. Yang W. Pruning DNA: structure-specific endonucleases (XPF/Rad1/Mus81). Structure 2003, 11(4):365-366.
36. Brookman K.W., Lamerdin J.E., Thelen M.P., et al. ERCC4 (XPF) encodes a human nucleotide excision repair protein with eukaryotic recombination homologs. Mol Cell Biol 1996, 16(11):6553-6562.
37. Bessho T., Sancar A., Thompson L.H., Thelen M.P. Reconstitution of human excision nuclease with recombinant XPF- ERCC1 complex. J Biol Chem 1997, 272(6):3833-3837.
38. Al-Minawi A.Z., Lee Y.F., Hakansson D., et al. The ERCC1/XPF endonuclease is required for completion of homologous recombination at DNA replication forks stalled by inter-strand cross-links. Nucl Acids Res 2009, 37(19):6400-6413.
39. Kuraoka I., Kobertz W.R., Ariza R.R., Biggerstaff M., Essigmann J.M., Wood R.D. Repair of an interstrand DNA cross-link initiated by ERCC1-XPF repair/recombination nuclease. J Biol Chem 2000, 275(34):26632-26636.
40. Munoz P., Blanco R., Flores J.M., Blasco M.A. XPF nuclease-dependent telomere loss and increased DNA damage in mice overexpressing TRF2 result in premature aging and cancer. Nat Genet 2005, 37(10):1063-1071.
41. Niedernhofer L.J., Essers J., Weeda G., et al. The structure-specific endonuclease Ercc1-Xpf is required for targeted gene replacement in embryonic stem cells. EMBO J 2001, 20(22):6540-6549.
42. Niedernhofer L.J., Odijk H., Budzowska M., et al. The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks. Mol Cell Biol 2004, 24(13):5776-5787.
43. Schiestl R.H., Prakash S. RAD10, an excision repair gene of Saccharomyces cerevisiae, is involved in the RAD1 pathway of mitotic recombination. Mol Cell Biol 1990, 10(6):2485-2491.
44. Zhu X.D., Niedernhofer L., Kuster B., Mann M., Hoeijmakers J.H., de L.T. ERCC1/XPF removes the 3' overhang from uncapped telomeres and represses formation of telomeric DNA-containing double minute chromosomes. Mol Cell 2003, 12(6):1489-1498.
45. deLaat W.L., Appeldoorn E., Jaspers N.G.J., Hoeijmakers J.H.J. DNA structural elements required for ERCC1-XPF endonuclease activity. J Biol Chem 1998, 273(14):7835-7842.
46. Sijbers A.M., de Laat W.L., Ariza R.R., et al. Xeroderma pigmentosum group F caused by a defect in a structure-specific DNA repair endonuclease. Cell 1996, 86(5):811-822.
47. Enzlin J.H., Scharer O.D. The active site of the DNA repair endonuclease XPF-ERCC1 forms a highly conserved nuclease motif. EMBO J 2002, 21(8):2045-2053.
48. Tripsianes K., Folkers G., Ab E., et al. The structure of the human ERCC1/XPF interaction domains reveals a complementary role for the two proteins in nucleotide excision repair. Structure 2005, 13(12):1849-1858.
49. Tsodikov O.V., Enzlin J.H., Scharer O.D., Ellenberger T. Crystal structure and DNA binding functions of ERCC1, a subunit of the DNA structure-specific endonuclease XPF-ERCC1. Proc Natl Acad Sci USA 2005, 102(32):11236-11241.
50. de Laat W.L., Appeldoorn E., Sugasawa K., Weterings E., Jaspers N.G.J., Hoeijmakers J.H.J. DNA-binding polarity of human replication protein A positions nucleases in nucleotide excision repair. Genes Devel 1998, 12(16):2598-2609.
51. Tsodikov O.V., Ivanov D., Orelli B., et al. Structural basis for the recruitment of ERCC1-XPF to nucleotide excision repair complexes by XPA. EMBO J 2007, 26(22):4768-4776.
52. Einhorn L.H. Curing metastatic testicular cancer. Proc Natl Acad Sci USA 2002, 99(7):4592-4595.
53. Bellmunt J., Paz-Ares L., Cuello M., et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol 2007, 18(3):522-528.
54. Hoffmann A.C., Wild P., Leicht C., et al. MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia 2010, 12(8):628-636.
55. Olaussen K.A., Dunant A., Fouret P., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006, 355(10):983-991.
56. Ricceri F., Guarrera S., Sacerdote C., et al. ERCC1 haplotypes modify bladder cancer risk: a case-control study. DNA Repair (Amst) 2010, 9(2):191-200.
57. Su D., Ma S., Liu P., et al. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. Lung Cancer 2007, 56(2):281-288.
58. Ferry K.V., Hamilton T.C., Johnson S.W. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells - role of ERCC1-XPF. Biochem Pharmacol 2000, 60(9):1305-1313.
59. Li Q.D., Yu J.J., Mu C.J., et al. Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res 2000, 20(2A):645-652.
60. Reed E., Yu J.J., Davies A., Gannon J., Armentrout S.L. Clear cell tumors have higher mRNA levels of ERCC1 and XPB than other histological types of epithelial ovarian cancer. Clin Cancer Res 2003, 9(14):5299-5305.
61. Liu C., Zhou S., Begum S., et al. Increased expression and activity of repair genes TDP1 and XPF in non-small cell lung cancer. Lung Cancer 2007, 55(3):303-311.
62. Arora S., Kothandapani A., Tillison K., Kalman-Maltese V., Patrick S.M. Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells. DNA Repair (Amst) 2010, 9(7):745-753.
63. Chang I.Y., Kim M.H., Kim H.B., et al. Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin. Biochem Biophys Res Commun 2005, 327(1):225-233.
64. Cummings M., Higginbottom K., McGurk C.J., et al. XPA versus ERCC1 as chemosensitising agents to cisplatin and mitomycin C in prostate cancer cells: role of ERCC1 in homologous recombination repair. Biochem Pharmacol 2006, 72(2):166-175.
65. Graf N., Ang W.H., Zhu G., Myint M., Lippard S.J. Role of Endonucleases XPF and XPG in nucleotide excision repair of platinated DNA and cisplatin/oxaliplatin cytotoxicity. Chembiochem 2011, 12(7):1115-1123.
66. Selvakumaran M., Pisarcik D.A., Bao R., Yeung A.T., Hamilton T.C. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res 2003, 63(6):1311-1316.
67. Balin-Gauthier D., Delord J.P., Pillaire M.J., et al. Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation. Br J Cancer 2008, 98(1):120-128.
68. Prewett M., Deevi D.S., Bassi R., et al. Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab. Clin Cancer Res 2007, 13(24):7432-7440.
69. Yacoub A., McKinstry R., Hinman D., Chung T., Dent P., Hagan M.P. Epidermal growth factor and ionizing radiation up-regulate the DNA repair genes XRCC1 and ERCC1 in DU145 and LNCaP prostate carcinoma through MAPK signaling. Radiat Res 2003, 159(4):439-452.
70. O'Donovan A., Scherly D., Clarkson S., Wood R. Isolation of active recombinant XPG protein, a human DNA repair endonuclease. J Biol Chem 1994, 269:15965-15968.
71. Riedl T., Hanaoka F., Egly J.M. The comings and goings of nucleotide excision repair factors on damaged DNA. EMBO J 2003, 22(19):5293-5303.
72. Wakasugi M., Reardon J.T., Sancar A. The non-catalytic function of XPG protein during dual incision in human nucleotide excision repair. J Biol Chem 1997, 272(25):16030-16034.
73. Walsh C.S., Ogawa S., Karahashi H., et al. ERCC5 is a novel biomarker of ovarian cancer prognosis. J Clin Oncol 2008, 26(18):2952-2958.
74. Stevens E.V., Nishizuka S., Antony S., et al. Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers. Mol Cancer Ther 2008, 7(1):10-18.
75. Sun X., Li F., Sun N., et al. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients. Lung Cancer 2009, 65(2):230-236.
76. Hicham Alaoui-Ismaili M., Gervais C., Brunette S., Gouin G., Hamel M., Rando R.F., et al. A novel high throughput screening assay for HCV NS3 helicase activity. Antiviral Res 2000, 46(3):181-193.
77. Belon C.A., Frick D.N. Monitoring helicase activity with molecular beacons. Biotechniques 2008, 45(4):433-440. 442.
78. Selby C.P., Sancar A. Molecular mechanism of transcription-repair coupling [see comments]. Science 1993, 260(5104):53-58.
79. Buratowski S. DNA repair and transcription: the helicase connection. Science 1993, 260(5104):37-38.
80. Schaeffer L., Roy R., Humbert S., et al. DNA repair helicase: a component of BTF2 (TFIIH) basic transcription factor. Science 1993, 260(5104):58-63.
81. Fan L., Arvai A.S., Cooper P.K., Iwai S., Hanaoka F., Tainer J.A. Conserved XPB core structure and motifs for DNA unwinding: implications for pathway selection of transcription or excision repair. Mol Cell 2006, 22(1):27-37.
82. Fan L., Fuss J.O., Cheng Q.J., et al. XPD helicase structures and activities: insights into the cancer and aging phenotypes from XPD mutations. Cell 2008, 133(5):789-800.
83. Glanzer J.G., Liu S., Oakley G.G. Small molecule inhibitor of the RPA70 N-terminal protein interaction domain discovered using in silico and in vitro methods. Bioorg Med Chem 2011, 19(8):2589-2595.
84. Haring S.J., Mason A.C., Binz S.K., Wold M.S. Cellular functions of human RPA1. Multiple roles of domains in replication, repair, and checkpoints. J Biol Chem 2008, 283(27):19095-19111.
85. Hass C.S., Gakhar L., Wold M.S. Functional characterization of a cancer causing mutation in human replication protein A. Mol Cancer Res 2010, 8(7):1017-1026.
86. Turchi J.J., Shuck S.C., Short E.A., Andrews B.J. Targeting nucleotide excision repair as a mechanism to increase cisplatin efficacy. Platinum and other heavy metal compounds in cancer chemotherapy 2009, 177-188. Humana Press, New York. A. Bonetti, R. Leone, F.M. Muggia, S.B. Howell (Eds.).
87. Andrews B.J., Turchi J.J. Development of a high-throughput screen for inhibitors of replication protein A and its role in nucleotide excision repair. Mol Cancer Ther 2004, 3(4):385-391.
88. Shuck S.C., Turchi J.J. Targeted inhibition of Replication Protein A reveals cytotoxic activity, synergy with chemotherapeutic DNA-damaging agents, and insight into cellular function. Cancer Res 2010, 70(8):3189-3198.
89. Neher T.M., Shuck S.C., Liu J., Zhang J.T., Turchi J.J. Identification of novel small molecule inhibitors of the XPA protein using in silico based screening. ACS Chem Biol 2010, 5(10):953-965.